The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
 
Alfredo Addeo
Honoraria - AZD; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Lilly; MSD; Pfizer; Roche
 
Markus Joerger
No Relationships to Disclose
 
Sacha Rothschild
Honoraria - AZD (Inst); Roche (Inst)
Consulting or Advisory Role - AZD (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Eisai (Inst); Lilly (Inst); Pfizer (Inst)
 
Eric I. Eboulet
No Relationships to Disclose
 
Gilles Godar
No Relationships to Disclose
 
Christine Waibel-Pachinger
No Relationships to Disclose
 
Simon Haefliger
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst)
 
Michael Thomas Mark
Consulting or Advisory Role - AstraZeneca; bms; Roche; Takeda
Travel, Accommodations, Expenses - Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
EUGENIO FERNANDEZ
No Relationships to Disclose
 
Nicolas Mach
Honoraria - Amgen; AZD; Bristol-Myers Squibb; Merck; MSD
 
Laetitia A. Mauti
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Roche; Takeda
 
Martin Frueh
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Lilly (Inst); MSD (Inst); Roche (Inst); Roche (Inst); Takeda (Inst)
Speakers' Bureau - Pfizer (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); BMS (Inst)